about
Hit to lead evaluation of 1,2,3-triazolo[4,5-b]pyridines as PIM kinase inhibitorsDiscovery of a potent, selective, and orally active phosphodiesterase 10A inhibitor for the potential treatment of schizophreniaPI3Kα inhibition reduces obesity in miceRAB7 counteracts PI3K-driven macropinocytosis activated at early stages of melanoma developmentOptimizing the performance of in silico ADMET general models according to local requirements: MARS approach. solubility estimations as case study.Design and synthesis of a series of piperazine-1-carboxamidine derivatives with antifungal activity resulting from accumulation of endogenous reactive oxygen species.Discovery of mitogen-activated protein kinase-interacting kinase 1 inhibitors by a comprehensive fragment-oriented virtual screening approach.A novel phosphatidylinositol 3-kinase (PI3K) inhibitor directs a potent FOXO-dependent, p53-independent cell cycle arrest phenotype characterized by the differential induction of a subset of FOXO-regulated genesTherapeutic inhibition of TRF1 impairs the growth of p53-deficient K-RasG12V-induced lung cancer by induction of telomeric DNA damageAlternative Activation Mechanisms of Protein Kinase B Trigger Distinct Downstream Signaling Responses.A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations.Dihydrothiazolopyridone derivatives as a novel family of positive allosteric modulators of the metabotropic glutamate 5 (mGlu5) receptorGeneration of tricyclic imidazo[1,2-a]pyrazines as novel PI3K inhibitors by application of a conformational restriction strategy.Rapid identification of ETP-46992, orally bioavailable PI3K inhibitor, selective versus mTOR.Biological characterization of ETP-46321 a selective and efficacious inhibitor of phosphoinositide-3-kinases.Imidazo[1,2-a]pyrazines as novel PI3K inhibitors.Pim 1 kinase inhibitor ETP-45299 suppresses cellular proliferation and synergizes with PI3K inhibition.Synthesis of 3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazoles, displaying combined 5-HT uptake inhibiting and alpha(2)-adrenoceptor antagonistic activities: a novel series of potential antidepressants.Synthesis of 3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazoles, displaying combined 5-HT uptake inhibiting and alpha2-adrenoceptor antagonistic activities. Part 2: Further exploration on the cinnamyl moiety.Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking activity.Inhibition of TRF1 Telomere Protein Impairs Tumor Initiation and Progression in Glioblastoma Mouse Models and Patient-Derived Xenografts.Identification of novel PI3K inhibitors through a scaffold hopping strategy.Non-genotoxic activation of p53 through the RPL11-dependent ribosomal stress pathway.Tissue damage and senescence provide critical signals for cellular reprogramming in vivo.Solid-Phase Synthesis of Macrocyclic Systems by a Cyclorelease Strategy: Application of the Stille Coupling to a Synthesis of (S)-Zearalenone.ETP-46321, a dual p110α/δ class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritis.Pharmacological inhibition of PI3K reduces adiposity and metabolic syndrome in obese mice and rhesus monkeys.Identification of ETP-46321, a potent and orally bioavailable PI3K α, δ inhibitor.Azino-Fused Benzimidazolium Salts as DNA Intercalating Agents. 2Tricyclic isoxazolines: Identification of R226161 as a potential new antidepressant that combines potent serotonin reuptake inhibition and α2-adrenoceptor antagonismPolymer-supported selenium reagents for organic synthesisSolid Phase Synthesis of Macrocycles by an Intramolecular Ketophosphonate Reaction. Synthesis of a (dl)-Muscone LibraryUnexpected NC bond fission of fused N-alkylbenzimidazolium salts. A new approach to pyrido[1,2-a]- or pyridazino[1,6-a]benzimidazolesA General and Highly Efficient Solid Phase Synthesis of Oligosaccharides. Total Synthesis of a Heptasaccharide Phytoalexin Elicitor (HPE)Synthesis of new azino fused benzimidazolium salts. a new family of DNA intercalating agents. IPreclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancerThe targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN statusDiscovery of novel triazolo[4,3-b]pyridazin-3-yl-quinoline derivatives as PIM inhibitorsAnti-tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL-302 in neuroblastomaScreening protocol for the identification of modulators by immunofluorescent cell-based assay
P50
Q27676829-89AA35D8-0CB1-4666-B42F-8A929FC1AE7AQ27690092-17DE10FA-C7F5-49F0-AABC-6076C3797C7AQ28818545-8B305A92-E2AC-45C3-A2FA-8195F8B47BB2Q30657002-92CD065B-471B-4D37-84DC-942D6CCD0BA2Q30887386-7BF0CF10-608D-42CE-9087-E788372C347DQ33496497-5828E583-4863-4B62-8AC0-6FA8D3668895Q33665113-A0BF1496-1BD7-49A9-94FA-E380CD49AD56Q35000701-B9DD5467-165B-4B32-BB92-CD6D8BB7B5E9Q35904248-021BE333-4B28-4CFA-BB26-30723B54A0FFQ36139887-D65462BA-9234-4A92-BD47-5A6CFD29112FQ36908567-093F472B-41E6-40AE-9EA3-4D521DF81B63Q37585074-A45A78E6-B724-48EB-9DAE-1639BD5B4F7BQ38839701-7A24581B-7206-4F95-9B9E-FC1B18966920Q39310774-7F058BC1-C4BA-44BD-B77B-12AED3B96BACQ39343270-F91B9BE0-6CAF-4000-B76B-1880B383CCEAQ39398071-6E0F5C31-1D64-46EA-9F8D-C5648199E502Q39635683-A44918CF-9ADB-4A0D-B2AD-D9E23E91ECACQ44520564-4754A32B-836E-420D-BB20-89DBE3D4184EQ44882691-851EE922-87F9-42C1-AB2B-BB34FDA9500DQ46383120-5C95E7EB-5B10-4A18-B86C-0776D1E4E590Q47404698-66708DD7-C8C3-4D2B-8055-312BAF80495AQ47669882-69787E7D-156C-4215-A6FA-2394E71DC8FCQ47974412-AA959457-1012-498A-A28C-0C9A690C2886Q51304904-1C97E940-516E-4375-B20C-F56563FBC293Q52715111-87934C11-24B6-473F-9FC7-0F245700ADCCQ53251314-150D0D30-DEE1-4026-A706-D7D444E17948Q54281359-5C0B3ED3-D6B1-47D2-A6CB-75B7022B6CCAQ54516102-15DF7525-0E0F-43B9-91B7-96D35BAA6E55Q56979342-1CB9F81A-A2D0-460D-86FD-6B17B3939EDBQ58136475-84F18884-AED6-4C33-A3C6-8CF7894BFBB2Q58136489-654FBA10-0B49-49C1-8D6D-09414DAF82F1Q58136496-14CA68C7-6024-4B46-8143-FB84FDA2F595Q58136506-B8AAE582-5A82-4355-9980-E8E239DF7A62Q58136510-A3E3C8B6-0F56-4564-9A56-D63D7EA29BE5Q58136524-7A7E0BBC-55F9-4C53-8674-3B698753C4A1Q89637594-2DEA3A2A-2444-4901-A8FC-1B0FE49DF266Q91525301-7F26F175-7147-43F7-A09F-11B953A35590Q91893455-89D5DA51-8108-4EF8-98A2-41CE2E71D97BQ92509850-5D4952CE-53AE-45C9-B5CD-F52521981330Q93008128-63A11145-5B49-4DB9-8987-EFEA90A2C149
P50
description
acteur
@nl
actor
@en
attore
@it
name
Joaquín Pastor
@ast
Joaquín Pastor
@en
Joaquín Pastor
@es
Joaquín Pastor
@nl
乔昆·帕斯特
@zh
華金·帕斯特
@zh-hant
type
label
Joaquín Pastor
@ast
Joaquín Pastor
@en
Joaquín Pastor
@es
Joaquín Pastor
@nl
乔昆·帕斯特
@zh
華金·帕斯特
@zh-hant
prefLabel
Joaquín Pastor
@ast
Joaquín Pastor
@en
Joaquín Pastor
@es
Joaquín Pastor
@nl
乔昆·帕斯特
@zh
華金·帕斯特
@zh-hant
P1053
I-4567-2015
P106
P21
P31
P345
P3829
P496
0000-0003-0553-8021
P569
1989-01-01T00:00:00Z